Panmure Liberum says OxfordBiomedica share fall overdone after Novartis and BMS pause trials

Oxford BioMedica (OXB) remains rated 'buy' by Panmure Liberum despite OXB shares dropping 15% after two customers paused autoimmune CAR‑T enrollment. Novartis and Bristol Myers Squibb voluntarily halted enrolment due to safety issues, signaling trial risk for the customer programs. While the selloff is significant, the analyst view is still supportive, suggesting near-term caution rather than a thesis break.

Analysis

The market is likely overstating the immediate P&L hit to OXB and understating the real risk: utilization slippage. For a CDMO, the damage from a customer trial pause is usually not lost revenue on day one, but delayed process-development work, slower batch throughput, and weaker visibility into follow-on manufacturing orders. That matters more for valuation than the headline because the stock had been pricing a cleaner ramp in cell-and-gene therapy volumes; if pauses extend, the multiple can compress even if booked revenue only defers.

For NVS, the economic impact is probably small relative to group earnings, but the strategic signal is bigger: autoimmune CAR-T remains a long-duration option, not a near-term profit engine. A safety-driven pause increases the probability that management re-phases spend toward better-controlled assets, which is negative for enthusiasm but not necessarily for intrinsic value. The second-order effect is a read-through to the broader cell-therapy basket: names with heavy exposure to bespoke ex-vivo platforms can see multiple pressure if investors start discounting a slower regulatory/commercial path.

The contrarian view is that voluntary pauses often reduce tail risk rather than amplify it; teams are trying to avoid a larger safety event. If the issue is program-specific rather than platform-wide, this is more a timeline reset than a thesis break. The key falsifier is a second customer or a second indication showing the same safety pattern, or OXB commentary implying manufacturing pull-through is being canceled rather than deferred over the next 1-2 quarters.

Key Decisions for Investors

• No immediate short in OXB on this print; wait for evidence of lost manufacturing volume or utilization decline in the next update before expressing a bearish view.
• Long NVS vs short XBI on any broader biotech weakness over the next 1-4 weeks: NVS has limited direct earnings exposure to the pause, while XBI carries more sentiment risk from safety read-throughs.
• If OXB gaps lower again on no new negative data, consider a tactical mean-reversion long only after management confirms no platform-wide safety issue; stop out if the pause broadens to additional programs.
• Set an alert for any revision to NVS cell-therapy spend or guidance over the next 1-2 quarters; a cut would confirm this is a portfolio-prioritization event, not just a temporary enrollment pause.